Nutritional Intervention for Biliary Atresia

Launched by TONGJI HOSPITAL · Jan 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a special type of nutrition formula—called medium-chain triglyceride (MCT) formula—can help infants with biliary atresia (BA) grow better and improve their nutrition. Biliary atresia is a condition where the bile ducts in the liver are blocked or absent, which can lead to malnutrition because these babies often struggle to absorb nutrients properly. The trial will compare the effects of intensified feeding with the MCT formula to traditional feeding methods during a critical time around surgery (known as the perioperative period). The goal is to see if the MCT formula helps improve growth and overall health in these infants.

To participate in this study, infants must be under 3 months old and have a confirmed diagnosis of biliary atresia, along with the need for a specific surgery called Kasai surgery. Parents or guardians will need to give their permission for their child to join the study and help with follow-up care. Unfortunately, some infants won’t be able to participate, such as those who are very low birth weight or have other serious health issues. This study is not yet recruiting participants, but it aims to provide important insights into how better nutrition can support young children facing biliary atresia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Infants under 3 months old; 2. Children clinically diagnosed with biliary atresia and in need of Kasai surgery; 3. The patient themselves, legal representative or guardian have signed the informed consent form and are willing to actively cooperate with treatment and follow-up.
• Exclusion Criteria:
• • 1. Low birth weight infants or very low birth weight infants; 2. Complicated with life-threatening diseases of various organ systems; 3. Complicated with other severe digestive tract malformations or other diseases that may interfere with the treatment of the patient or the patient's compliance; 4. Patients who have participated in other clinical trials within the last month; 5. Any other conditions that the researcher deems unsuitable for participation in this trial.